Mind Medicine Inc (STU:MMQ)
€ 6.875 0.17 (2.54%) Market Cap: 494.11 Mil Enterprise Value: 271.67 Mil PE Ratio: 0 PB Ratio: 2.67 GF Score: 40/100

Mind Medicine (MindMed) Inc at Canaccord Genuity Growth Conference Transcript

Aug 10, 2022 / 03:00PM GMT
Release Date Price: €9.22 (+9.43%)
Tania Gonsalves
Canaccord Genuity Group Inc. - Analyst

(audio in progress) Barrow, the CEO of Mind Medicine. Mind Medicine or MindMed for short is a neuro-pharmaceutical company developing psychedelic-inspired medicines. Its clinical programs include the study of an ibogaine derivative for opioid withdrawal and addiction and the study of LSD for ADHD and anxiety, as well as pain.

Mr. Barrow joined MindMed as Chief Development Officer earlier this -- earlier last year. And few months later, he was promoted to CEO -- so very quickly -- briefly served as Director of Drug Development and Discovery at Usona Institute. And this is a not-for-profit. He was actually one of the early incumbents in the psychedelic research space. They were looking at psilocybin for depression, similar to many other companies in the space.

Now, Robert, I would like to invite you to join me up here on the podium to tell our investors a little bit about MindMed. I would like to remind everyone, please hold your questions for the end. We will give you five minutes to ask questions after the presentation.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot